A Phase 3b Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial
Latest Information Update: 26 Nov 2025
At a glance
- Drugs Retatrutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms TRIUMPH-8
- Sponsors Eli Lilly and Company
Most Recent Events
- 26 Nov 2025 New trial record